Acrivon Therapeutics, Inc. IPO Advisory
Share this IPO Profile:Smart Search
Company |
Symbol |
Price Range |
Issue Price |
Open |
Shares |
Trade Date |
| Acrivon Therapeutics, Inc. | ACRV - NASDAQ |
$16.00-$18.00 | $12.50 | $13.35 | 7.5 million | 11/15/2022 |
| Jefferies, Cowen, Piper Sandler | ||||||
Co-Manager(s): | ||||||
| Health Care | ||||||
Filing(s): Filed 2022-10-17 Terms Added 2022-11-03 | ||||||
Acrivon Therapeutics, Inc. Quote & Chart - Click for current quote - ACRV
IPO Boutique aggregates information on public companies and private companies, such as "ACRV" IPO, which is intended to educate our readers and help them evaluate potential investment opportunities and market conditions. We endeavor to research the financial industry and obtain independent verification of factual statements before presenting them to our users. Be informed.
About Acrivon Therapeutics, Inc. (adapted from Acrivon Therapeutics, Inc. prospectus):
They are a clinical stage biopharmaceutical company developing precision oncology medicines that we match to patients whose tumors are predicted to be sensitive to each specific medicine by utilizing our proprietary proteomics-based patient responder identification platform.
This description is adapted from prospectus. This description is not intended to be a recommendation to buy stock from this company. To see the company's full description, view their prospectus.
They are a clinical stage biopharmaceutical company developing precision oncology medicines that we match to patients whose tumors are predicted to be sensitive to each specific medicine by utilizing our proprietary proteomics-based patient responder identification platform.
This description is adapted from prospectus. This description is not intended to be a recommendation to buy stock from this company. To see the company's full description, view their prospectus.
IPO Boutique aggregates information on public companies and private companies, such as "ACRV" IPO, which is intended to educate our readers and help them evaluate potential investment opportunities and market conditions. We endeavor to research the financial industry and obtain independent verification of factual statements before presenting them to our users. Be informed.